168 related articles for article (PubMed ID: 26135631)
1. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA.
Shen M; Wu MY; Chen LP; Zhi Q; Gong FR; Chen K; Li DM; Wu Y; Tao M; Li W
Sci Rep; 2015 Jul; 5():11836. PubMed ID: 26135631
[TBL] [Abstract][Full Text] [Related]
2. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis.
Li W; Xie L; Chen Z; Zhu Y; Sun Y; Miao Y; Xu Z; Han X
Cancer Sci; 2010 May; 101(5):1226-33. PubMed ID: 20331621
[TBL] [Abstract][Full Text] [Related]
3. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin.
Wu MY; Xie X; Xu ZK; Xie L; Chen Z; Shou LM; Gong FR; Xie YF; Li W; Tao M
Oncol Rep; 2014 Aug; 32(2):513-22. PubMed ID: 24926961
[TBL] [Abstract][Full Text] [Related]
4. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
[TBL] [Abstract][Full Text] [Related]
5. The radiotherapy-sensitization effect of cantharidin: Mechanisms involving cell cycle regulation, enhanced DNA damage, and inhibited DNA damage repair.
Xu MD; Liu SL; Zheng BB; Wu J; Wu MY; Zhang Y; Gong FR; Tao M; Zhang J; Li W
Pancreatology; 2018 Oct; 18(7):822-832. PubMed ID: 30201439
[TBL] [Abstract][Full Text] [Related]
6. Cantharidin suppressed breast cancer MDA-MB-231 cell growth and migration by inhibiting MAPK signaling pathway.
Gu XD; Xu LL; Zhao H; Gu JZ; Xie XH
Braz J Med Biol Res; 2017 Jul; 50(7):e5920. PubMed ID: 28678918
[TBL] [Abstract][Full Text] [Related]
7. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway.
Li W; Chen Z; Zong Y; Gong F; Zhu Y; Zhu Y; Lv J; Zhang J; Xie L; Sun Y; Miao Y; Tao M; Han X; Xu Z
Cancer Lett; 2011 May; 304(2):117-27. PubMed ID: 21376459
[TBL] [Abstract][Full Text] [Related]
8. PP2A inhibitors arrest G2/M transition through JNK/Sp1- dependent down-regulation of CDK1 and autophagy-dependent up-regulation of p21.
Gong FR; Wu MY; Shen M; Zhi Q; Xu ZK; Wang R; Wang WJ; Zong Y; Li ZL; Wu Y; Zhou BP; Chen K; Tao M; Li W
Oncotarget; 2015 Jul; 6(21):18469-83. PubMed ID: 26053095
[TBL] [Abstract][Full Text] [Related]
9. Role of cantharidin in the activation of IKKα/IκBα/NF‑κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines.
Zhou H; Xu J; Wang S; Peng J
Mol Med Rep; 2018 Jun; 17(6):7672-7682. PubMed ID: 29620225
[TBL] [Abstract][Full Text] [Related]
10. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib.
Wang WJ; Wu MY; Shen M; Zhi Q; Liu ZY; Gong FR; Tao M; Li W
Int J Oncol; 2015 Nov; 47(5):1912-22. PubMed ID: 26398277
[TBL] [Abstract][Full Text] [Related]
11. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of α2 integrin.
Shou LM; Zhang QY; Li W; Xie X; Chen K; Lian L; Li ZY; Gong FR; Dai KS; Mao YX; Tao M
Oncol Rep; 2013 Sep; 30(3):1059-66. PubMed ID: 23835679
[TBL] [Abstract][Full Text] [Related]
12. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer.
Xu MD; Liu L; Wu MY; Jiang M; Shou LM; Wang WJ; Wu J; Zhang Y; Gong FR; Chen K; Tao M; Zhi Q; Li W
Oncogenesis; 2018 Nov; 7(11):94. PubMed ID: 30478299
[TBL] [Abstract][Full Text] [Related]
13. A novel cantharidin analog N-benzylcantharidinamide reduces the expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic translocation of HuR.
Lee JY; Chung TW; Choi HJ; Lee CH; Eun JS; Han YT; Choi JY; Kim SY; Han CW; Jeong HS; Ha KT
Biochem Biophys Res Commun; 2014 May; 447(2):371-7. PubMed ID: 24735540
[TBL] [Abstract][Full Text] [Related]
14. Cantharidin impairs cell migration and invasion of A375.S2 human melanoma cells by suppressing MMP-2 and -9 through PI3K/NF-κB signaling pathways.
Ji BC; Hsiao YP; Tsai CH; Chang SJ; Hsu SC; Liu HC; Huang YP; Lien JC; Chung JG
Anticancer Res; 2015 Feb; 35(2):729-38. PubMed ID: 25667452
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic effect of cantharidin in A549 human lung cancer cells.
Kim YM; Ku MJ; Son YJ; Yun JM; Kim SH; Lee SY
Arch Pharm Res; 2013 Apr; 36(4):479-84. PubMed ID: 23435912
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway.
Xie X; Wu MY; Shou LM; Chen LP; Gong FR; Chen K; Li DM; Duan WM; Xie YF; Mao YX; Li W; Tao M
Oncol Lett; 2015 Feb; 9(2):837-844. PubMed ID: 25624908
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac.
Tao M; Liu L; Shen M; Zhi Q; Gong FR; Zhou BP; Wu Y; Liu H; Chen K; Shen B; Wu MY; Shou LM; Li W
Cell Cycle; 2016; 15(3):381-93. PubMed ID: 26761431
[TBL] [Abstract][Full Text] [Related]
19. CIL-102 induces matrix metalloproteinase-2 (MMP-2)/MMP-9 down-regulation via simultaneous suppression of genetic transcription and mRNA stability.
Liu WH; Chen YL; Chang LS
Int J Biochem Cell Biol; 2012 Dec; 44(12):2212-22. PubMed ID: 22964005
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
Kim MH; Shim KS; Kim SH
Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
